SLC5A2 and chronic kidney disease: Alternatively, the increasing use of novel effective anti-diabetic therapies (e.g., SGLT-2 inhibitors, GLP-1 analogues) could also have benefits on kidney complications [21, 23–25], however, it is unlikely to explain the very low number of identified CKD cases after such a short-term of their clinical application.